Axil Brands vs Solesence
AXIL and SLSN side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXIL and SLSN compare
Solesence is the larger company, worth 3.0 times as much as Axil Brands ($107M against $35.4M).
On earnings, Axil Brands is cheaper: it trades at 15.3× trailing earnings, against 38.0× for Solesence.
Axil Brands grew revenue faster over the last twelve months (10.3% versus −2.0% for Solesence).
Axil Brands keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with 4.5% at Solesence.
Axil Brands scores higher on the StockData Score (19 against 17 for Solesence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXIL | SLSN |
|---|---|---|
| Size and price | ||
| Market cap | $35.4M | $107M |
| Share price | $5.19 | $1.52 |
| Change, 1 year | 5.5% | −21.6% |
| Change, 5 years | 72.7% | −62.9% |
| Beta (5Y) | 0.50 | 1.46 |
| Employees | 13 | 115 |
| StockData Score | ||
| Total score | 19 (better) | 17 |
| Valuation score | 6 (better) | 4 |
| Growth score | 3 | 3 |
| Performance score | 4 | 5 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 15.3× (better) | 38.0× |
| P/S | 1.2× (better) | 1.8× |
| P/B | 2.6× (better) | 6.4× |
| EV/EBITDA | 8.5× (better) | 21.9× |
| P/FCF | 8.1× | – |
| PEG | 0.31 | – |
| FCF yield | 12.3% | – |
| Fair value | $12.61 | $1.96 |
| Margin of safety | 58.8% (better) | 22.6% |
| Growth | ||
| Revenue growth (TTM) | 10.3% (better) | −2.0% |
| Revenue growth, 5Y average | 80.0% (better) | 29.4% |
| Net income growth (TTM) | 114% | 365% (better) |
| EPS growth (TTM) | 113% | 300% (better) |
| EPS growth, 5Y average | – | 5.9% |
| Profitability | ||
| Gross margin | 72.4% (better) | 31.7% |
| Operating margin | 10.0% (better) | 6.0% |
| Net margin | 9.3% (better) | 4.5% |
| FCF margin | 14.5% | – |
| Return on equity | 23.3% (better) | 18.2% |
| Return on invested capital | 43.2% (better) | 20.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.31 (better) | 1.73 |
| Altman Z-score | 7.63 (better) | 1.09 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.06% |
| Shareholder yield | 0.00% (better) | −0.06% |
| Ownership | ||
| Held by institutions | 15.6% | 4.5% |
| Held by insiders | 69.6% | 75.2% |
| Insider net buying, 12 months | – | $4.8K |
| Short interest, % of float | 0.48% | 2.1% |
Go deeper
- AXIL stock overview
- AXIL income statement
- AXIL valuation and score
- SLSN stock overview
- SLSN income statement
- SLSN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.